Virax Biolabs Group Ltd
VRAX
Company Profile
Business description
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
Contact
Bo’Ness Road Newhouse
BioCity Glasgow
LondonML1 5UH
GBRT: +44 2077887414
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
19
Stocks News & Analysis
stocks
Tough conditions for ASX listed wagering leader
Wagering continues to be challenged in Australia.
stocks
Chart of the Week: Inflation fears dampen sentiment on retailers
Rising inflation is the fly in the ointment.
stocks
Here’s 3 Top Rated ASX shares for 2026
As we start the new year, let’s take a closer look at three compelling opportunities on the ASX
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,046.50 | 22.30 | 0.25% |
| CAC 40 | 8,243.47 | 9.55 | 0.12% |
| DAX 40 | 25,127.46 | 5.20 | 0.02% |
| Dow JONES (US) | 49,266.11 | 270.03 | 0.55% |
| FTSE 100 | 10,044.69 | 3.52 | -0.04% |
| HKSE | 26,149.31 | 309.64 | -1.17% |
| NASDAQ | 23,480.02 | 104.26 | -0.44% |
| Nikkei 225 | 51,117.26 | 844.72 | -1.63% |
| NZX 50 Index | 13,733.06 | 16.20 | 0.12% |
| S&P 500 | 6,921.46 | 0.53 | 0.01% |
| S&P/ASX 200 | 8,720.80 | 18.20 | 0.21% |
| SSE Composite Index | 4,082.98 | 2.79 | -0.07% |